|
|
|
|
|
|
by Consultant32452
2082 days ago
|
|
|
One example: >The second reason, the authors noted, is that there isn't significant competition in the U.S. insulin market. Price competition typically comes from the introduction of a generic drug that directly competes with a branded product. >But the authors said that current insulin makers have blocked the entry to such products by getting new patents based on things such as a new delivery device. https://www.usnews.com/news/health-news/articles/2019-11-07/... Patent reform would help bring generics on the market and reduce prices. |
|
|